188 related articles for article (PubMed ID: 29262532)
21. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
Best SA; Harapas CR; Kersbergen A; Rathi V; Asselin-Labat ML; Sutherland KD
Oncogene; 2018 Nov; 37(46):6096-6104. PubMed ID: 29991799
[TBL] [Abstract][Full Text] [Related]
22. Extra-CNS and dural metastases in
Kleinschmidt-DeMasters BK; Gilani A
Neurooncol Pract; 2022 Oct; 9(5):449-455. PubMed ID: 36134017
[TBL] [Abstract][Full Text] [Related]
23. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
24. Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).
Hallal M; Braga-Lagache S; Jankovic J; Simillion C; Bruggmann R; Uldry AC; Allam R; Heller M; Bonadies N
BMC Cancer; 2021 Jul; 21(1):789. PubMed ID: 34238254
[TBL] [Abstract][Full Text] [Related]
25. Integration of conventional quantitative and phospho-proteomics reveals new elements in activated Jurkat T-cell receptor pathway maintenance.
Jouy F; Müller SA; Wagner J; Otto W; von Bergen M; Tomm JM
Proteomics; 2015 Jan; 15(1):25-33. PubMed ID: 25348772
[TBL] [Abstract][Full Text] [Related]
26. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.
Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T
Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236
[TBL] [Abstract][Full Text] [Related]
27. RNAi technology targeting the
Parker Kerrigan BC; Ledbetter D; Kronowitz M; Phillips L; Gumin J; Hossain A; Yang J; Mendt M; Singh S; Cogdell D; Ene C; Shpall E; Lang FF
Neurooncol Adv; 2020; 2(1):vdaa132. PubMed ID: 33241214
[TBL] [Abstract][Full Text] [Related]
28. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
[TBL] [Abstract][Full Text] [Related]
29. Glioblastoma,
Broggi G; Piombino E; Altieri R; Romano C; Certo F; Barbagallo GMV; Vigneri P; Condorelli D; Colarossi L; Colarossi C; Magro G; Tirrò E
Front Neurol; 2022; 13():823015. PubMed ID: 35222252
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer.
Dhami J; Hirshfield KM; Ganesan S; Hellmann M; Rojas V; Amorosa JK; Riedlinger GM; Zhong H; Ali SM; Pavlick D; Elvin JA; Rodriguez-Rodriguez L
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29588307
[No Abstract] [Full Text] [Related]
31. Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration.
Banella C; Ginevrino M; Catalano G; Fabiani E; Falconi G; Divona M; Curzi P; Panetta P; Voso MT; Noguera NI
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):163-168. PubMed ID: 32199932
[TBL] [Abstract][Full Text] [Related]
32. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate.
Akbulut O; Lengerli D; Saatci O; Duman E; Seker UOS; Isik A; Akyol A; Caliskan B; Banoglu E; Sahin O
Mol Cancer Ther; 2020 Jun; 19(6):1243-1254. PubMed ID: 32217742
[TBL] [Abstract][Full Text] [Related]
33. Successful Treatment and Retreatment With Erdafitinib for a Patient With
Pham C; Lang D; Iams WT
JTO Clin Res Rep; 2023 May; 4(5):100511. PubMed ID: 37214414
[No Abstract] [Full Text] [Related]
34. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines.
Still IH; Vince P; Cowell JK
Genomics; 1999 Jun; 58(2):165-70. PubMed ID: 10366448
[TBL] [Abstract][Full Text] [Related]
35. TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness.
Saatci O; Sahin O
Cell Cycle; 2023; 22(23-24):2637-2655. PubMed ID: 38197196
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and Molecular Characteristics of
Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255
[TBL] [Abstract][Full Text] [Related]
37. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
[TBL] [Abstract][Full Text] [Related]
38. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
[TBL] [Abstract][Full Text] [Related]
39. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract][Full Text] [Related]
40. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Georgescu MM; Islam MZ; Li Y; Traylor J; Nanda A
Acta Neuropathol Commun; 2021 Apr; 9(1):69. PubMed ID: 33853673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]